CONSIDERATIONS TO KNOW ABOUT SIFALIMUMAB

MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Primary demo goals were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or